In a landmark Phase 2 obesity trial, participants receiving the highest dose achieved: Up to ~24% average weight loss at 48 weeks Weight loss had not yet plateaued at the end of the study Potential for even greater reductions with longer treatment duration For context: Semaglutide (GLP-1): ~15% weight loss Tirzepatide (GIP + GLP-1): ~2123% weight loss Retatrutide (GIP + GLP-1 + Glucagon): ~24%+ weight loss in Phase 2 studies Common side effects were similar to other GLP-1based therapies and included nausea, vomiting, diarrhea, constipation, and abdominal discomfort, primarily during dose escalation
Its important to note, however, that the highest dose for semaglutide is now 2.2 mg (versus 1 mg used in the study), so more direct comparison is needed
Richardson, The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease
53 National Library of Medicine (2023c)
This article selected 50 newborns with pneumonia from Qiqihar Medical University, Second Affiliated Hospital, to ensure the representativeness and consistency of the sample
Semaglutide and tirzepatide are large peptide molecules with molecular weights exceeding 4,000 daltons, a threshold that typically prevents significant transfer into breast milk
